FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215702511> ?p ?o ?g. }

• W3215702511 endingPage "2034" @default.
• W3215702511 startingPage "2019" @default.
• W3215702511 abstract "Anti-human epidermal growth factor receptor 2 (HER2) therapy is an effective treatment for HER2-positive gastric and breast malignancies. However, the efficacy of HER2-targeted therapy in non-small cell lung cancer (NSCLC) patients with HER2 alterations remains controversial. We searched studies on HER2-targeted therapy in NSCLC patients that reported objective response rate (ORR), disease control rate (DCR) and progressionfree survival (PFS) published from database inception to 30 May 2021. A total of 32 trials involving 958 patients were included. The ORRs of HER2-TKIs targeted therapy, humanised monoclonal antibody, trastuzumab-based treatment and antibody-drug conjugate (ADC) (T-DM1) were 22% (95% CI 11-31), 23% (95% CI 20-65), 26% (95% CI 14-39) and 16% (95% CI _6-37), while that of ADC (DS-8201) was 60% (95% CI 35-85). The DCRs of these groups were 59% (95% CI 49-69), 39% (95% CI _9-88), 63% (95% CI 37-89), 31% (95% CI 4-58) and 87% (95% CI 62-112), respectively. In the subgroup analysis, numerically higher ORRs and DCRs were observed in the poziotinib (38%; 75%) and pyrotinib (35%; 83%) groups. The median PFSs of these groups were 5.51 months, 3.09 months, 4.61 months, 2.65 months and 12.04 months, respectively. HER2-targeted therapy can be considered an acceptable treatment strategy for NSCLC patients with HER2 alterations. In particular, ADC (DS-8201), pyrotinib and poziotinib demonstrated promising anti-tumour activity in HER2-positive NSCLC." @default.
• W3215702511 created "2021-12-06" @default.
• W3215702511 creator A5026906414 @default.
• W3215702511 creator A5035555370 @default.
• W3215702511 creator A5061594674 @default.
• W3215702511 date "2021-12-21" @default.
• W3215702511 modified "2023-10-15" @default.
• W3215702511 title "Efficacy of targeted therapy in patients with HER2‐positive non‐small cell lung cancer: A systematic review and meta‐analysis" @default.
• W3215702511 cites W1966071998 @default.
• W3215702511 cites W1984007340 @default.
• W3215702511 cites W1985620074 @default.
• W3215702511 cites W1996910928 @default.
• W3215702511 cites W2007010878 @default.
• W3215702511 cites W2008166288 @default.
• W3215702511 cites W2030375470 @default.
• W3215702511 cites W2046050735 @default.
• W3215702511 cites W2057180889 @default.
• W3215702511 cites W2069271031 @default.
• W3215702511 cites W2073698378 @default.
• W3215702511 cites W2087669085 @default.
• W3215702511 cites W2100439220 @default.
• W3215702511 cites W2107562400 @default.
• W3215702511 cites W2112854176 @default.
• W3215702511 cites W2114095518 @default.
• W3215702511 cites W2116531504 @default.
• W3215702511 cites W2125744030 @default.
• W3215702511 cites W2130043727 @default.
• W3215702511 cites W2133208325 @default.
• W3215702511 cites W2136028687 @default.
• W3215702511 cites W2146274229 @default.
• W3215702511 cites W2148527073 @default.
• W3215702511 cites W2156098321 @default.
• W3215702511 cites W2159192794 @default.
• W3215702511 cites W2175694606 @default.
• W3215702511 cites W2262992387 @default.
• W3215702511 cites W2314772071 @default.
• W3215702511 cites W2387397851 @default.
• W3215702511 cites W246286872 @default.
• W3215702511 cites W2510264042 @default.
• W3215702511 cites W2570599275 @default.
• W3215702511 cites W2577651608 @default.
• W3215702511 cites W2583905538 @default.
• W3215702511 cites W2613098450 @default.
• W3215702511 cites W2735084022 @default.
• W3215702511 cites W2736996422 @default.
• W3215702511 cites W2760931533 @default.
• W3215702511 cites W2767597066 @default.
• W3215702511 cites W2783112448 @default.
• W3215702511 cites W2785515282 @default.
• W3215702511 cites W2785610956 @default.
• W3215702511 cites W2799596353 @default.
• W3215702511 cites W2801651204 @default.
• W3215702511 cites W2805369673 @default.
• W3215702511 cites W2883614966 @default.
• W3215702511 cites W2885615830 @default.
• W3215702511 cites W2889646458 @default.
• W3215702511 cites W2889957730 @default.
• W3215702511 cites W2896939494 @default.
• W3215702511 cites W2897221567 @default.
• W3215702511 cites W2898457249 @default.
• W3215702511 cites W2898502827 @default.
• W3215702511 cites W2907907709 @default.
• W3215702511 cites W2912998652 @default.
• W3215702511 cites W2913258427 @default.
• W3215702511 cites W2915968104 @default.
• W3215702511 cites W2939173235 @default.
• W3215702511 cites W2944073323 @default.
• W3215702511 cites W2947410094 @default.
• W3215702511 cites W2976352116 @default.
• W3215702511 cites W2977889895 @default.
• W3215702511 cites W2985843002 @default.
• W3215702511 cites W2987002164 @default.
• W3215702511 cites W3013632168 @default.
• W3215702511 cites W3020500179 @default.
• W3215702511 cites W3024789690 @default.
• W3215702511 cites W3032438306 @default.
• W3215702511 cites W3037442044 @default.
• W3215702511 cites W3038770224 @default.
• W3215702511 cites W3040877059 @default.
• W3215702511 cites W3088045239 @default.
• W3215702511 cites W3088586143 @default.
• W3215702511 cites W3135105663 @default.
• W3215702511 cites W3136127895 @default.
• W3215702511 cites W3136317587 @default.
• W3215702511 cites W3201244536 @default.
• W3215702511 cites W3215702511 @default.
• W3215702511 doi "https://doi.org/10.1111/bcp.15155" @default.
• W3215702511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34820879" @default.
• W3215702511 hasPublicationYear "2021" @default.
• W3215702511 type Work @default.
• W3215702511 sameAs 3215702511 @default.
• W3215702511 citedByCount "11" @default.
• W3215702511 countsByYear W32157025112021 @default.
• W3215702511 countsByYear W32157025112022 @default.
• W3215702511 countsByYear W32157025112023 @default.
• W3215702511 crossrefType "journal-article" @default.
• W3215702511 hasAuthorship W3215702511A5026906414 @default.
• W3215702511 hasAuthorship W3215702511A5035555370 @default.

• next